摘要
选择经皮冠状动脉腔内成形术(PTCA)成功的冠心病患者,观察血府逐瘀浓缩丸对PTCA后再狭窄的预防作用。结果表明:西药常规治疗组复发心绞痛15例(15/38),其中12例重复冠状动脉造影证实有11例再狭窄形成,另3例心电图活动平板复查示相关导联阳性,治疗前后血瘀证候积分值无明显变化(P>0.05);加血府逐瘀浓缩丸组6例复发心绞痛(6/35),心绞痛复发率显著低于西药常规治疗组(P<0.01),其中5例重复冠状动脉造影复查证实有4例再狭窄形成,4例无心绞痛复发者重复冠状动脉造影证实无再狭窄形成,治疗后血瘀证候积分值比治疗前明显下降(P<0.01)。PTCA后心绞痛复发与“血瘀证”关系的分析发现,复发心绞痛患者血瘀证候积分值显著高于未复发心绞痛患者。血府逐瘀浓缩丸可改善PTCA患者的血瘀症状,对预防PTCA后再狭窄有一定的作用。
Cases with coronary heart disease after successful PTCA were selected for observation of the preventive' action of CXZP on restenosis of the vessel. Results revealed that (1) In the western medicine group 15 cases experienced recurrent angina pectoris. Among them, 12 cases received repeated angiography, 11 of them were confirmed to have restenosis while the 3 other cases were positive in ECG exercise treadmill test. No obvious changes were observed in stasis integration before and after treatment (P<0. 05). (2) Only six cases had recurrent angina in the group with CXZP, markedly lower than that of the control group (P<0. 01) . Of them, 4 cases were confirmed to have restenosis, where as the 4 cases without angina were confirmed to have no restenosis and the stasisintegration was markedly lowered than that before treatment ( P< 0. 01). Analysis on the relation between recurrent angina and "blood stasissyndrome" after PTCA revealed that the stasis integration in recurrent group was markedly higher than that in nonrecurrent group, demonstrating that CXZP can distinctively improve the stasis symptoms and yield certain action on the prevention of restenosis in PTCA.
出处
《中医杂志》
CSCD
北大核心
1997年第1期27-29,共3页
Journal of Traditional Chinese Medicine
基金
国家中医药管理局"八.五"攻关课题
关键词
冠心病
PTCA
手术后
再狭窄
预防
血府逐瘀丸
Coronary arterial diseases/surgical operation coronary shunt stenoais
pathological/ prevention and control @ CXZP
